TECH

BIO-TECHNE Corp

NasdaqAdd to watchlist

Healthcare · Biotechnology

$72.43

−$0.02−0.03%

Delayed · 2026-09-04T20:00:00.000Z · marketstack

2 of 47tracked managers hold this· Q2 2026

Aug 11, 2026$72.43

+$0.28+0.39%over 1M

Day range38% of range

$72.40$72.48

Session

Previous close: $72.45
Open: $72.40
Volume: 1.86M
Avg volume: -
Day high: $72.48
Day low: $72.40

Fundamentals

Visualize fundamentals and more

Market cap: 11.3B
P/E ratio: -
EPS (TTM): -
Dividend yield: -
Beta: 1.27
Shares outstanding: 155.96M

Source SEC EDGAR · 9/11/2026

Tracked investors

As of Q2 2026 · 73 days ago · next update ~14 Nov 2026· what moved this quarter, onMeasure

2 fund managers this platform follows disclosed a position in TECH, from quarterly SEC filings up to 45 days old; a manager may have sold since without yet having to say so.

Ruane, Cunniff & Goldfarb
Sequoia Fund
$236.6M
3.68%of book
Joel Greenblatt
Gotham Asset Management
$5.03M
0.01%of book

Manager	Position	Share of their book	Last change
Ruane, Cunniff & Goldfarb Sequoia Fund	$236.6M	3.68%
Joel Greenblatt Gotham Asset Management	$5.03M	0.01%

Share price, with each quarter a tracked manager’s position changed shaded across the range it traded in.

406080

now

Q4 '22

Q1 '23

Q1 '25

Q2 '25

Q3 '25

Q4 '25

Q1 '26

Q2 '26

Hover a shaded quarter to see it moved. Who, and the range they traded in, is onBespoke

13F filings cover US-listed shares only (not cash, bonds, shorts, or private holdings) and are never a recommendation to do the same.

Risk factors, year on year

Item 1AAugust 2026 10-KAugust 2025as filed.

added: 38
dropped: 10
re-drafted: 18

Out of 127 passages in this year’s Item 1A.

The assistant has not been given these passages. It will say so, and say what opens them. This costs you no question.

New this year

International political, compliance and business factors, including the military conflicts and trade tensions, can negatively impact our operations and financial results.

47 more passages, included withBespoke

Recent activity

Sep 9Additional proxy materialCompany filingDEFA14A

19 more events, included withMeasure

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Companies like BIO-TECHNE Corp

Also filed under Biotechnology, ranked by how closely they sit beside TECH.

MRNAModerna, Inc.
ALNYALNYLAM PHARMACEUTICALS, INC.
REGNREGENERON PHARMACEUTICALS, INC.
VRTXVERTEX PHARMACEUTICALS INC / MA
INSMINSMED Inc
ARGXARGENX SE

Ask about BIO-TECHNE Corp

The assistant answers from what TECH has actually filed: 18 annual reports filed with the SEC, 13F positions from the 2 tracked investors who hold it and 6 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Pressing one answers it here, from TECH's filings and figures. One a day without an account; a free account has its own, and no card.

See every investor holding BIO-TECHNE Corp, and every quarter they moved.

Ten seconds, no card, and nothing to cancel.

What an account lets you do with BIO-TECHNE Corp

Separate the decisions from the paperwork
Every Form 4 TECH insiders have filed, with vesting and automatic tax sales struck out: what's left is the buys and sells somebody actually chose to make.
Every filingMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: who added, who trimmed, who walked away.
Every position they holdMeasure
Interrogate the filing, not the internet
Ask anything about BIO-TECHNE Corp's fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free accountSee what the paid plans add

Free, no card, and it does not expire.